A single 8 Gy or 20 Gy in five daily fractions were commonly
employed. At the 1 month follow-up, all Brief Pain Inventory functional interference scores showed a highly significant decrease from baseline (P < 0.01). From our study population, 58 (64%) were classified as responders and 57 (46%) as non-responders to radiotherapy. We compared the urinary markers between the responders and the non-responders. There were no statistically significant MLN4924 cost differences between the two groups either in terms of baseline markers or in terms of month 1 follow-up markers. There was no significant change from baseline to the 1 month follow-up in responders or in non-responders to radiotherapy.
Conclusion: Baseline levels of urinary markers could not predict which patient would benefit from palliative radiotherapy. Chow, E. et al. (2009). Clinical Oncology 21, 336-342 (c) 2009 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.”
“Purpose: To validate the Swedish version of the Distress Thermometer
(DT) against the Hospital Anxiety and Depression Scale (HADS) for screening of distress and to explore how well DT measures changes of distress during six months in a population of heterogeneous oncology patients.
Methods: The DT was translated into Swedish according to the forward- and back-translation procedure. HADS total score >= 15 was used as gold standard. Consecutive patients were invited to participate at their first STI571 in vitro visit to the Oncology department. The HADS and the DT were completed at baseline and after I, 3 and 6 months.
Results: click here 462 baseline and 321 six-month assessments were completed. The patients had a variety of cancer diagnoses (n = 42). Most patients (95%) received active treatment. The DT compared favourably with the HADS. The area under the curve was 0.86 (95% CI, 0.82-0.90). DT >= 4 showed a sensitivity of 87%, a specificity of
73%, a positive predictive value (PPV) of 52% and a negative predictive value (NPV) of 95% at baseline. The results from the 1, 3 and 6 months assessments were equivalent baseline results. The DT means changed in the same direction as HADS at all points of assessment. Patients with distress reported statistically significantly more problems in all categories on the associated ‘Problem List’ compared to non-distressed patients.
Conclusion: The Swedish version of the DT with a score >= 4 is valid for screening of distress in heterogeneous oncology patients. Its ability to measure changes in distress over time is comparable to HADS. (c) 2012 Elsevier Ltd. All rights reserved.”
“This study describes the effect of treatment of Bis(3-triethoxysilyl propyl)tetrasulfane (silane coupling agent, Si69, TESPT) on in situ sodium activated, organo modified bentonite clay – styrene butadiene rubber (SBR) nanocomposite.